

# Datasheet for ABIN7601080 anti-TOE1 antibody (AA 28-501)



#### Overview

Quantity:	100 μg
Target:	TOE1
Binding Specificity:	AA 28-501
Reactivity:	Human
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This TOE1 antibody is un-conjugated
Application:	Western Blotting (WB), ELISA, Immunofluorescence (IF), Immunocytochemistry (ICC), Flow Cytometry (FACS)

### **Product Details**

Purpose:	Anti-TOE1 Antibody Picoband®
Immunogen:	E.coli-derived human TOE1 recombinant protein (Position: E28-Q501).
Isotype:	IgG
Cross-Reactivity (Details):	No cross-reactivity with other proteins.
Characteristics:	Anti-TOE1 Antibody Picoband® (ABIN7601080). Tested in ELISA, Flow Cytometry, IF, ICC, WB applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.
Purification:	Immunogen affinity purified.

#### **Target Details**

Target:	TOE1
Alternative Name:	TOE1 (TOE1 Products)
Background:	Synonyms: Interleukin-36 alpha, FIL1 epsilon, Interleukin-1 epsilon, IL-1 epsilon, Interleukin-1
	family member 6, IL-1F6, IL36A, FIL1E, IL1E, IL1F6
	Tissue Specificity: Expressed in immune system and fetal brain, but not in other tissues tested
	or in multiple hematopoietic cell lines. Predominantly expressed in skin keratinocytes but not in
	fibroblasts, endothelial cells or melanocytes. Increased in lesional psoriasis skin.
	Background: Target of EGR1 protein 1 is a protein that in humans is encoded by the TOE1 gene
	Enables poly(A)-specific ribonuclease activity and snRNA binding activity. Involved in RNA
	phosphodiester bond hydrolysis, exonucleolytic and snRNA 3'-end processing. Located in Cajal
	body and cytoplasm. Implicated in pontocerebellar hypoplasia type 7.
Molecular Weight:	57 kDa
Gene ID:	114034
	114034
Application Details	114034 Western blot, 0.1-0.25 μg/mL, Human
Application Details	
Application Details	Western blot, 0.1-0.25 μg/mL, Human
Application Details	Western blot, 0.1-0.25 μg/mL, Human Immunocytochemistry/Immunofluorescence, 5 μg/mL, Human
Application Details	Western blot, 0.1-0.25 μg/mL, Human Immunocytochemistry/Immunofluorescence, 5 μg/mL, Human Flow Cytometry(Fixed), 1-3 μg/1x10 <sup>6</sup> cells, Human
Gene ID:  Application Details  Application Notes:	Western blot, 0.1-0.25 μg/mL, Human Immunocytochemistry/Immunofluorescence, 5 μg/mL, Human Flow Cytometry(Fixed), 1-3 μg/1x10 <sup>6</sup> cells, Human ELISA, 0.1-0.5 μg/mL, -
Application Details	Western blot, 0.1-0.25 μg/mL, Human Immunocytochemistry/Immunofluorescence, 5 μg/mL, Human Flow Cytometry(Fixed), 1-3 μg/1x10 <sup>6</sup> cells, Human ELISA, 0.1-0.5 μg/mL, -  1. Anderson, C., Davies, J. H., Lamont, L., Foulds, N. Early pontocerebellar hypoplasia with
Application Details	Western blot, 0.1-0.25 μg/mL, Human Immunocytochemistry/Immunofluorescence, 5 μg/mL, Human Flow Cytometry(Fixed), 1-3 μg/1x10 <sup>6</sup> cells, Human ELISA, 0.1-0.5 μg/mL, -  1. Anderson, C., Davies, J. H., Lamont, L., Foulds, N. Early pontocerebellar hypoplasia with vanishing testes: a new syndrome? Am. J. Med. Genet. 155A: 667-672, 2011. 2. Brault, L. S.,
Application Details	Western blot, 0.1-0.25 μg/mL, Human Immunocytochemistry/Immunofluorescence, 5 μg/mL, Human Flow Cytometry(Fixed), 1-3 μg/1x10 <sup>6</sup> cells, Human ELISA, 0.1-0.5 μg/mL, -  1. Anderson, C., Davies, J. H., Lamont, L., Foulds, N. Early pontocerebellar hypoplasia with vanishing testes: a new syndrome? Am. J. Med. Genet. 155A: 667-672, 2011. 2. Brault, L. S., Cooper, C. A., Famula, T. R., Murray, J. D., Penedo, M. C. T. Mapping of equine cerebellar
Application Details	Western blot, 0.1-0.25 μg/mL, Human Immunocytochemistry/Immunofluorescence, 5 μg/mL, Human Flow Cytometry(Fixed), 1-3 μg/1x10 <sup>6</sup> cells, Human ELISA, 0.1-0.5 μg/mL, -  1. Anderson, C., Davies, J. H., Lamont, L., Foulds, N. Early pontocerebellar hypoplasia with vanishing testes: a new syndrome? Am. J. Med. Genet. 155A: 667-672, 2011. 2. Brault, L. S., Cooper, C. A., Famula, T. R., Murray, J. D., Penedo, M. C. T. Mapping of equine cerebellar abiotrophy to ECA2 and identification of a potential causative mutation affecting expression of
Application Details	Western blot, 0.1-0.25 μg/mL, Human Immunocytochemistry/Immunofluorescence, 5 μg/mL, Human Flow Cytometry(Fixed), 1-3 μg/1x10 <sup>6</sup> cells, Human ELISA, 0.1-0.5 μg/mL, -  1. Anderson, C., Davies, J. H., Lamont, L., Foulds, N. Early pontocerebellar hypoplasia with vanishing testes: a new syndrome? Am. J. Med. Genet. 155A: 667-672, 2011. 2. Brault, L. S., Cooper, C. A., Famula, T. R., Murray, J. D., Penedo, M. C. T. Mapping of equine cerebellar abiotrophy to ECA2 and identification of a potential causative mutation affecting expression of MUTYH. Genomics 97: 121-129, 2011. 3. de Belle, I., Wu, JX., Sperandio, S., Mercola, D.,

## Handling

Format:	Lyophilized
Reconstitution:	Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL.
Concentration:	500 μg/mL

## Handling

Buffer:	Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.
Storage:	4 °C,-20 °C
Storage Comment:	At -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.  It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freezing and thawing.